Coherus Oncology, Inc. (CHRS) Hires Oppenheimer to Sell Legacy Biosim Assets; CVRs in Place

Coherus Oncology retained Oppenheimer to market and sell its legacy biosimilar assets. Holders of CVRs, to be distributed to stockholders of record on Sept. 30, 2026, will receive their pro rata share of any net proceeds from a sale or licensing of these assets.Material DetailsContext by AI Analyst…